Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | DUT | P33316 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15827068 | 0.91 | MAPT (0.49) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL6522822 | 0.90 | TK1 (0.46) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL465454 | 0.90 | TK1 (0.46) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL14168221 | 0.88 | KIF11 (0.53) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL9613450 | 0.88 | TK1 (0.45) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL4917240 | 0.88 | KIF11 (0.53) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL4771137 | 0.88 | TK1 (0.48) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL21087595 | 0.88 | TK1 (0.48) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL10772460 | 0.87 | TK1 (0.54) | KIF11TK1CTSKDUTALOX15 | |
| SCHEMBL16281907 | 0.87 | KIF11 (0.50) | KIF11TK1CTSKDUTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117186145-B | Preparation method of glyceraldehyde-3-phosphoric acid | 长沙晨辰医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117186145-A | Preparation method of glyceraldehyde-3-phosphoric acid | 长沙晨辰医药科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| EP-0036155-A2 | Polymerisable phospholipids, process for their preparation, polymeric phospholipids, process for their preparation as well as the use of the polymeric phospholipids | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1981-09-23 | — | — | EP | claimed |
| CN-117186145-B | Preparation method of glyceraldehyde-3-phosphoric acid | 长沙晨辰医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117186145-A | Preparation method of glyceraldehyde-3-phosphoric acid | 长沙晨辰医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2017090007-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND HEPATIC DISEASES | RAO M SURYA (IN) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017090007-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND HEPATIC DISEASES | RAO M SURYA (IN) | 2017-06-01 | — | — | WO | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9511150-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-8907079-B2 | Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof | CELLMOSAIC INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20090156801-A1 | BIOMOLECULE LABELING REACTANTS BASED ON AZACYCLOALKANES AND CONJUGATES DERIVED THEREOF | NXP B.V. (NL) | 2009-06-18 | — | — | US | disclosed |
| EP-2016060-A1 | BIOMOLECULE LABELING REACTANTS BASED ON AZACYCLOALKANES AND CONJUGATES DERIVED THEREOF | Wallac OY (FI) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007128874-A1 | BIOMOLECULE LABELING REACTANTS BASED ON AZACYCLOALKANES AND CONJUGATES DERIVED THEREOF | WALLAC OY (FI) | 2007-11-15 | — | — | WO | disclosed |
| US-5374646-A | Treatment or prophylasix of hypertension and diseases associated with cognitive disorders | GLAXO GROUP LIMITED (GB) | 1994-12-20 | — | — | US | disclosed |
| EP-0434249-A2 | Benzofuran derivatives | GLAXO GROUP LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| EP-0152965-B1 | PROCESS FOR PREPARING 2,6-SUBSTITUTED-9-(1,3-DIHYDROXY-2-PROPOXY-MENTHYL)-PURINES AND CERTAIN DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1990-10-24 | — | — | EP | disclosed |
| EP-0002062-B1 | CYCLIC ORGANOPHOSPHORUS COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1982-05-05 | — | — | EP | disclosed |
| EP-0036155-A2 | Polymerisable phospholipids, process for their preparation, polymeric phospholipids, process for their preparation as well as the use of the polymeric phospholipids | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1981-09-23 | — | — | EP | disclosed |
| EP-0002062-A1 | Cyclic organophosphorus compounds, method for their preparation and their use | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | KIF11 370/4885TK1 1899/4885CTSK 3954/4885 |
| US-20090156801-A1 | BIOMOLECULE LABELING REACTANTS BASED ON AZACYCLOALKANES AND CONJUGATES DERIVED THEREOF | DNMT1, PTMS, DNMT3A | KIF11 2393/4885TK1 11/4885CTSK 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.